Objective: The aim of this study was to describe the school-age outcome of a cohort of children treated with intensive care support for persistent pulmonary hypertension of the newborn (PPHN).
Introduction
Inhaled nitric oxide (iNO) has been found to be an effective and safe treatment for persistent pulmonary hypertension (PPHN) in the term and near-term newborns. [1] [2] [3] [4] [5] The use of iNO has been found to improve oxygenation and decrease the need for extracorporeal membrane oxygenation (ECMO) in term newborns with acute respiratory failure and PPHN. [6] [7] [8] The use of iNO has now been extended to preterm infants as rescue therapy in infants with respiratory failure despite surfactant replacement therapy, as well as more widespread use in less sick infants in an attempt to decrease the frequency of chronic lung disease of the premature. [9] [10] [11] [12] [13] As use becomes more widespread, it remains important to continue to evaluate the short-and long-term outcomes for these infants.
Previous follow-up studies of children who were treated with iNO as neonates have not found a short-term increase in medical, neurodevelopmental or behavioral problems when compared historically or concurrently with infants treated conventionally or with ECMO. Several studies of children up to 2 years of age, who were treated with iNO as neonates in a cohort study at our site 14 and at other sites where iNO-treated infants were compared with controls in randomized trials, [15] [16] [17] have been fairly encouraging regarding short-term developmental outcomes. Furthermore, when interviewed, parents of slightly older children (up to 4 years of age) who were treated with iNO as infants in a single center randomized controlled trial of iNO use for PPHN did not report an increase in pulmonary, neurologic, cognitive, behavioral or neurosensory outcomes in infants treated with iNO when compared to those managed without iNO. 18 Although defined differently from study to study, neurodevelopmental disabilities have been reported in 10 to 30% of the young children with no differences noted when infants treated with iNO were compared with a control population treated for PPHN. These numbers were also comparable to a group of infants treated with ECMO followed out to 7 years of age. 19 Thus, outcomes for children treated as neonates for PPHN appear to be unrelated to the specifics of individual intensive care treatment regimens, rather to events clinically associated with PPHN such as perinatal asphyxia.
Overall, infants treated with iNO have outcomes similar to infants treated with ECMO and infants treated by conventional means for PPHN. However, to date, the functioning of infants treated with iNO who have reached school age has not been documented. This paper describes results of a prospective and longitudinal medical and neurodevelopmental follow-up at school age of a cohort of infants treated for PPHN with iNO and other modalities at the Children's Hospital in Denver.
Methods

Patient population
From April 1992 to December 1998, 187 infants were admitted to the Children's Hospital of Denver with a diagnosis of severe PPHN and treated in one of two study protocols that could involve iNO 4, 20 and subsequently a protocol that involved continued access to iNO before its approval by the Food and Drug Administration. All families of surviving infants were offered participation in a follow-up protocol. The progress of the children through the study period is depicted in Figure 1 . The children who were not seen did not differ in their degree of neonatal illness from the cohort who did come for follow-up. The families who were not seen had either changed address and could not be reached despite multiple attempts or elected not to participate in the follow-up portion of the study.
Neonatal management
Medical management of PPHN and respiratory failure as well as criteria for entrance into the pilot and subsequent randomized neonatal treatment protocols were as described in the initial publications. 4, 20 Patients were eligible for continued access use if they had respiratory failure and echocardiographic evidence of PPHN. The treatment protocol for iNO involved an initial dose of 20 p.p.m. for 4 h with subsequent reduction to 6 p.p.m. In the group who participated in the randomized multicenter study, infants were randomly assigned to receive either high-frequency oscillatory ventilation (HFOV) or iNO plus conventional ventilation. If the initial assignment resulted in treatment failure, the other treatment was used and finally both iNO and HFOV if necessary. Thus, a high percentage of this group were exposed to iNO (Figure 1 ). The HFOV therapy (SensorMedics model 3100A, Yorba Linda, CA, USA) used a high-volume treatment strategy of optimizing lung inflation and oxygenation. The continued access group received what was by that time standard care in our center of conventional treatment, continued access to iNO plus conventional ventilation, HFOV or HFOV plus iNO. The order of treatments was at the discretion of the attending neonatologist. In general, the approach was to first recruit lung volumes with conventional or high-frequency ventilation followed by iNO use. In all three groups, respiratory alkalosis was not used as a primary treatment for PPHN. Infants who failed all elements of these protocols (iNO and HFOV) were evaluated for ECMO. The criteria used for ECMO have been previously described.
14 Data recorded from the newborn period included sex, gestational age, birth weight and admitting diagnosis before entry into the trials or continued access use of iNO.
Follow-up program
All infants enrolled in the clinical trials who survived were offered participation in the follow-up program. All procedures that were part of the follow-up program were approved by the Colorado Multiple Institution Review Board. Informed consent for the program was given by one or both parents of each infant. Patients were seen at 3 months, 6 months, 1 year, 2 years 14 and at early school age (the focus of this report).
At the school-age visit, parents were interviewed to find out information regarding medical and developmental status. Information collected included medications used, services used (such as physical, occupational and speech therapy) and intercurrent hospitalizations. The diagnosis precipitating rehospitalization was determined from medical record review and contact with the child's primary care provider. Vision and hearing were assessed by a review of medical records. Previous hearing screen results were reviewed, and in cases where there was a history of hearing loss on previous exams, repeat formal audiologic exams were performed. Growth parameters were measured, neurologic exam was completed by a single examiner (AAR), oxygen saturations were measured in room air, and chest X-ray and echocardiogram were performed.
Psychometric data were gathered at the same 2-day visit. All examiners were doctoral level psychologists or predoctoral trainees in psychology supervised by licensed psychologists (KNV and DW). Test administrators were blind to children's birth histories and treatment group. Testing included measures of global cognitive functioning, adaptive behaviors, academic achievement, higher-order cognitive abilities and executive functions, and social/emotional/behavioral functioning. Psychometric measures used included the following:
Wechsler Preschool and Primary Scale of IntelligenceRevised (WPPSI-R) 21 or Wechsler Scale of Intelligence for Children-Third Edition (WISC-III), 22 a global measure of cognitive functioning (Full Scale Intelligence Quotient, FSIQ), with a standardization mean of 100 and s.d. of 15, that can be broken down into verbal cognitive skills (Verbal Intelligence Quotient, VIQ) and nonverbal cognitive skills (performance or nonverbal intelligence quotient, PIQ). Data for children tested using WISC-III and WPPSI-R were collapsed given that they have the same standardization mean and s.d. Vineland Adaptive Behavior Scales, 23 a parent report interview of an individual's every day behaviors and self-care skills, including communication, daily living skills, social skills and motor skills. The Vineland scale yields an overall composite score of adaptive functioning, the adaptive behavior composite, which has standardization mean of 100 and s.d. of 15. Kaufman Test of Educational Achievement (KTEA), 24 a measure of academic achievement, which includes assessment of reading, math and spelling skills. KTEA yields three composite scores with a mean of 100 and s.d. of 15. These include an overall battery composite, a reading composite and a math composite score. Children's Category Test (CCT; Level 1), 25 a nonverbal measure of higher-order cognitive abilities. It yields one composite T-score, which has a standardization mean of 50 and s.d. of 10. Wisconsin Card Sorting Test (WCST, computerized), 26 a measure sensitive to executive functions such as abstract thinking, problem solving, cognitive flexibility and ability to use immediate feedback to solve a task. It yields several scores. The three scores examined in the current research were categories completed (this is nonstandardized; children can complete between 0 and 6 categories), perseverative errors (a T-score with a mean of 50 and s.d. of 10) and total errors (a T-score with mean of 50 and s.d. of 10). Achenbach Child Behavior Checklist (CBCL; parent and teacher forms), 27 ,28 assessments of a child's behavior and social competency, as reported by parents and teachers. CBCL yields a number of composite scores. For the current purposes, T-scores (mean ¼ 50; s.d. ¼ 10) for total behavior problems, internalizing behavior problems and externalizing behavior problems are reported. Unfortunately, not all children had behavioral rating forms from all three informantsFmother, father and teacher. Thus, to maximize the number of participants with behavioral data, T-scores for total behaviors, internalizing and externalizing behaviors from all available raters (from 1 to 3) were averaged, so that each participant had one score that was an average of available data from the different raters.
Of the 109 children enrolled in the study, 108 participated in the cognitive and psychosocial evaluation. One child in the group not exposed to iNO did not complete the evaluation because the family attended the first day of the evaluation but did not attend the second day on which the psychometric data were gathered. Of the 108 children who completed the evaluation, 2 children (1 from the iNO group (1.54%) and 1 from the noniNO-exposed group (3.23%)) had profound cognitive impairments, and thus, could not complete traditional measures of intelligence, academic achievement or higher-order cognitive functioning. Thus, these two children were assigned the lowest score in the sample for the Wechsler scales and KTEA as an estimate of their abilities. This was carried out to insure that the mean scores in the iNO and non-iNO groups were not inflated due to missing School-age outcomes of PPHN AA Rosenberg et al data for children with the most significant cognitive impairments. Analyses were run with and without these children included in the sample and results were consistent. Thus, data are presented with estimates for these two children included in analyses. Degree of intellectual disability was defined as severe if the FSIQ score was less than 70 with or without cerebral palsy that prevented independent walking. Moderate intellectual disability was defined by an FSIQ score of 70 to 84 (between 1 and 2 standard deviations below the mean) with or without an abnormal neurologic exam.
Data analysis
Medical data analyses. The medical data were compared among three groups of patients; those exposed only to mechanical ventilation (non-iNO-exposed group), an iNO group and a group who went on to receive ECMO (all of whom were exposed to iNO). Categorical variables were analyzed using w 2 -analysis and continuous variables with an unpaired t-test.
Psychometric data analyses. Before conducting primary analyses, all data were inspected for deviations from normality. All psychometric measures were normally distributed, and thus, parametric statistics were used. More specifically, analysis of variance (ANOVA) was used, and children were compared across the three groupsFchildren who received iNO, children who received iNO and ECMO, and children who received ventilation therapy only. To look at the entire group exposed to iNO, we also performed comparison between the combined iNO plus ECMO group and the unexposed group.
Results
Description of patient population
Of the 187 patients enrolled in the three trials, 109 (73% of the survivors) attended the school-age follow-up portion of the protocol with the mean age at follow-up 7.1 years (Figure 1 ). The age range at the time of their visit was 5.1 to 10.6 years with all but 13 falling between 6.1 and 7.9 years of age. Only two children were less than 6 years of age at the time of testing. The neonatal clinical features of the infants seen at school age are presented in Supplementary  Table S1 . Medical outcome data at school age are presented in Table 1 . There was a considerable percentage of the entire population (24%) with respiratory problems (primarily reactive airways disease) and a larger number (60%) with abnormal chest radiographs with hyperexpansion and/or changes consistent with chronic lung disease. Of the total population, 26% had required at least one rehospitalization since newborn discharge with most of these occurring in years 1 and 2. Thirty children (28%) were receiving chronic medications, mostly for reactive airways disease or allergic symptomatology. Only four children were on medications for behavioral issues, seizures or tone problems due to cerebral palsy. None of the comparisons across groups reached statistical significance. In addition, the original diagnosis at neonatal intensive care unit admission did not influence the medical outcome at school age. In terms of findings on the neurologic exam at school age, 12 (11%) children had an abnormal assessment with no difference in frequency among the different patient groups.
School-age follow-up Global cognitive functioning and adaptive behavior. Results of the ANOVAs examining group differences on the Wechsler intelligence scales revealed no statistically significant differences among the three groups on FSIQ, VIQ or PIQ. These results are summarized in Table 2 . As can be seen, the mean scores for the three groups were within the average range for the population. There were also no statistical differences between the entire iNOexposed group (including the 12 ECMO patients) and the group not exposed to iNO. Similarly, for adaptive functioning, no significant differences were revealed among the groups on the adaptive behavior composite of the Vineland Adaptive Behavior Scales. There were no statistical differences between the entire iNOexposed group (including the 12 ECMO patients) and the group not exposed to iNO.
Academic achievement testing. Results for academic achievement testing using KTEA are also summarized in Table 2 . Again, no statistically significant differences among the three groups on KTEA battery composite, reading composite or math composite were found.
Higher cognitive abilities and executive functioning. Two measures were used to examine higher-order cognitive functioning and executive functioning, the CCT and WCST. Results of the ANOVAs revealed no significant differences among the three groups on the CCT or WCST (Table 2) .
Social/emotional/behavioral functioning. Results of the ANOVAs (see Table 2 ) examining total behavior problems, internalizing behaviors and externalizing behaviors from the Achenbach CBCL yielded no significant differences among groups, similar to cognitive measures described above.
Summary of school-age follow-up results. Taken together, cognitive and behavioral testing revealed no significant differences among the iNO, iNO þ ECMO and non-iNO-exposed groups. In addition, performance by these three groups on cognitive and behavioral testing was within the average range for the normative population. The overall rate of severe intellectual disability (FSIQ <70) across the three groups was 9.2% (10/108), with 7.4% (8/ 108) suffering a moderate intellectual disability (FSIQ of 70 to 84). There were no statistically significant differences in neurodevelopmental outcome found based on the original diagnosis associated with PPHN. There was a trend toward poorer outcome in the children with congenital diaphragmatic hernia (CDH) with an average FSIQ of 94.42 ± 26.08 and a 33% rate of moderate or severe handicap.
Of 109 children seen at school age, 98 (68 iNO exposed; 30 not exposed to iNO) were also seen at 2 years of age. The mean Bayley mental developmental index on the Bayley 2 scales was 101.8±18.7 and the mean psychomotor developmental index was 103.3 ± 17.5. Of 98 children, 8 (8.2%) were judged to have severe neurodevelopmental handicap with 6 of 98 (6.1%) showing a moderate handicap. Of the eight children judged to have severe handicap at age 2, five (62.5%) had severe handicap at school age whereas the other three had moderate handicap. All six classified with moderate handicap at age 2 were normal at school age. Among those children felt to be normal at age 2, one went on to show severe handicap at school age and one had moderate handicap.
Discussion
This study represents the first comprehensive evaluation of a cohort of school-age children that included a large number of infants treated with iNO for acute respiratory failure with pulmonary hypertension in the newborn period. The use of iNO has been an exciting advance in the treatment of PPHN of the term and nearterm newborns. Previous follow-up studies of children who were treated with iNO as neonates have not found a short-term increase in medical, neurodevelopmental or behavioral problems in this cohort when compared with children managed using ventilationonly therapies and ECMO. [14] [15] [16] [17] 19 We report a comprehensive follow-up at school age of a large cohort of infants, who previously would have been considered for treatment with ECMO, who were treated with iNO for PPHN. Only 12 of the infants (11%) went on to require ECMO.
We previously reported medical follow-up on a portion of these children at 1 and 2 years of age.
14 The feeding problems and need for supplemental oxygen reported at that time were resolved by school age. Persistent findings are the 6.4% rate of sensorineural hearing loss and pulmonary complications related to mechanical ventilation in the newborn period. Previous reports have also identified hearing loss as an issue in this population irrespective of method of management. 15,17,29 -34 The rate we report is lower than that seen in most other studies and possibly relates to the lack of respiratory alkalosis and infrequent use of pancuronium, both have which have been previously implicated as associations with sensorineural hearing loss. 33, 34 The relatively low incidence of hearing loss is also internally consistent with our initial 1-and 2-year follow-up data.
14 None of the children identified previously 'outgrew' their hearing loss so this possibility does not explain the incidence we report at school age. Although formal testing was not conducted on the entire cohort, parents did not report issues in school or with language development that might suggest unrecognized progressive hearing loss. The fact that repeat testing was not performed in all children at school age is a limitation of the study in that the incidence of mild degrees of hearing loss may be underestimated in these results. The pulmonary outcomes we describe are very similar to those described in children previously treated as newborns with ECMO for pulmonary hypertension. 35 The cardiac outcomes for this cohort were encouraging as well. Only one child had residual pulmonary hypertension. This was a child with CDH as well as an atrial septal defect that required surgical repair. 36 Neurodevelopmental outcome for this population was quite encouraging. There were no significant differences between children who had received iNO as neonates when compared with infants with PPHN managed without iNO on measures of global cognitive functioning, adaptive behaviors, academic achievement, higher-order cognitive abilities and executive functions, and social/ emotional/behavioral functioning. Overall performance on neurodevelopmental and behavioral testing was within the average range for the normative population. Most of our severely impaired patients had profound perinatal or postnatal hypoxic-ischemic insults, which supports the concept that outcome is determined by the severity of the neonatal course and types of conditions that predispose to pulmonary hypertension such as perinatal asphyxia.
There are several limitations of this study. Owing to the experimental design of the treatment trials, there are fewer noniNO-exposed patients than iNO-exposed children. Thus, there is not an adequately sized control population available for comparison.
In addition, in the continued access time period, the non-iNOexposed group likely includes a less ill cohort of patients and makes for a not well-matched control group. Nevertheless, it is reassuring that outcomes were similar between the two groups. In addition, the small number of infants who went on to require ECMO does not provide an adequate sample size for study. Thus, any conclusions about that group need to take this factor into consideration. The same comment can be made about the small group of children born with CDH who like the ECMO group showed a trend toward poorer neurodevelopmental outcome. Second, The sample size included here is smaller than the other instruments, because 15 participants were too young to complete the test, 10 participants had missing data due to computer or other error, 1 participant had problem behaviors that led the test to be discontinued early and 4 participants could not understand the demands of the task.
hearing was not assessed audiologically in the complete cohort, so the reported incidence of hearing loss may represent an underestimate. However, all children had hearing testing conducted at some point during the longitudinal follow-up (usually at 1 or 2 years of age), and those with a parental report of a problem were tested again at school age. It is unlikely that any children with significant hearing loss have been missed. It also needs to be noted that no developmental testing was conducted concurrently in a normal population. For all of the neurodevelopmental assessments, standardized norms were used. Thus, the overall rate of neurodevelopmental handicap in a population of children born without PPHN was not assessed.
In conclusion, we have reported school-age outcomes for a cohort of infants treated for PPHN at our institution. This cohort included a large group of infants treated with iNO. As was the case at ages 1 and 2, medical and neurodevelopmental outcomes at school age are similar to previous reports of infants with PPHN managed conventionally and with ECMO.
